Company Overview - Lianchi Hospital has submitted a listing application to the Hong Kong Stock Exchange, with China Galaxy International as the exclusive sponsor [1] - The company is positioned as a high-quality specialty medical group with a focus on patient-centered care and innovative medical service models [1] - By September 30, 2025, the company plans to operate 5 hospitals and 1 elderly care facility, with a total building area of approximately 117,900 square meters and 786 registered beds [1] Operational Performance - As of September 30, 2025, the company has a medical team consisting of 341 practicing physicians and assistant doctors [1] - The outpatient visits, inpatient admissions, orthopedic surgeries, and childbirths are expected to maintain a high level through 2023, 2024, and the first nine months of 2025 [1] - According to Frost & Sullivan, Lianchi Orthopedic Hospital ranks first in Shandong Province and third nationwide in terms of private hospital knee surgery volume for 2024 [1] Industry Trends - The Chinese healthcare service market is experiencing overall growth, with the private hospital sector being one of the fastest-growing components [2] - Revenue from private hospitals increased from RMB 437.9 billion in 2019 to RMB 689.2 billion in 2023, reflecting a compound annual growth rate (CAGR) of 12.0% [2] - It is projected that the revenue for private hospitals will reach RMB 1.88 trillion by 2030, with a CAGR of 12.2% from 2024 to 2030 [2]

Company Overview - Lianchi Hospital Group Co., Ltd. is a specialty medical group in China, operating five hospitals and one elderly care institution under a group management structure as of September 30, 2025 [3] - The company emphasizes a "patient-first" core value and implements a "human-centered medical" management model, creating a well-known medical brand called "Lianchi Medical" [3] - As of September 30, 2025, the total building area of the hospitals is approximately 117,893.06 square meters, with a total of 786 registered beds and a team of 341 practicing physicians and assistant doctors [3] Financial Performance - The company recorded revenues of approximately RMB 356.43 million, RMB 418.41 million, and RMB 358.57 million for the years ending December 31, 2023, December 31, 2024, and the nine months ending September 30, 2025, respectively [5][6] - The net profit for the same periods was RMB 56.73 million, RMB 67.59 million, and RMB 55.51 million [7] - Gross profit figures were approximately RMB 117.23 million, RMB 151.14 million, and RMB 127.63 million, with gross profit margins remaining stable at 35.0% for the nine months ending September 30, 2024, and 35.6% for the nine months ending September 30, 2025 [8] Industry Overview - The Chinese healthcare service market has been steadily improving, driven by increasing health awareness, expanded public health insurance coverage, and the rise of chronic diseases [9] - Total healthcare expenditure in China increased from RMB 6.58 trillion in 2019 to RMB 9.76 trillion in 2024, with a compound annual growth rate (CAGR) of 8.2% from 2019 to 2024 [9] - The number of private hospitals in China is projected to grow from 22,424 in 2019 to 26,956 by 2024, with a CAGR of 3.8% [15] Competitive Position - Lianchi Hospital's Zibo Lianchi Orthopedic Hospital ranks first in Shandong Province and third nationally in terms of private hospital knee surgery volume for 2024 [4] - The Chongqing Great Wall Orthopedic Hospital is ranked first among private orthopedic specialty hospitals in Southwest China based on revenue for 2024 [4]

Core Insights - The number of hospitals in China is projected to reach 38,710 by the end of 2024, with private hospitals numbering approximately 26,956, which is about 2.3 times the number of public hospitals at 11,754. However, private hospitals account for only about 1/5 of the core medical service metrics compared to public hospitals [2][3] Group 1: Hospital Statistics - In 2024, the total number of hospitals is 38,710, with public hospitals at 11,754 and private hospitals at 26,956 [2] - Public hospitals handled 3.77 billion outpatient visits and 210 million inpatient admissions, while private hospitals managed 730 million outpatient visits and 45 million inpatient admissions [2] - The number of community health service centers is projected to increase from 10,070 in 2023 to 10,228 in 2024 [1] Group 2: Industry Challenges and Development - The private hospital sector faces significant challenges, including tightening regulations, reduced operational space, and increased survival thresholds, necessitating compliance and refined management practices [3][4] - The industry has undergone three major development phases, with the current phase marked by stricter regulations and the impact of the pandemic [3] - Some listed companies are selling hospitals at low prices due to perceived lack of operational viability, indicating a potential trend of consolidation and survival of the fittest in the industry [4] Group 3: Future Outlook - The future of the private healthcare sector may see the exit of smaller, less effective hospitals, while those with strong management, market orientation, and specialized expertise are expected to thrive [4][5] - The industry is viewed as a valuable complement to the public healthcare system, emphasizing the need for a balanced perspective towards private healthcare [5]

Core Viewpoint - Ming Kee Hospital is a leading private for-profit hospital group in East China, with significant market share and a focus on providing high-quality medical services through its two hospitals in Nanjing and Suzhou [2][3]. Company Overview - Ming Kee Hospital operates two private for-profit general hospitals: Nanjing Ming Kee Hospital and Suzhou Ming Kee Hospital, making it the largest private for-profit hospital group in East China by total revenue in 2024, with a market share of 1.0% in the region and 0.4% nationally [2]. - Nanjing Ming Kee Hospital, operational since 2008, was rated as a tertiary hospital in 2022, becoming the first private hospital in Nanjing to achieve this status. It ranks as the third largest private for-profit hospital in China with a market share of 0.3% [2]. - Suzhou Ming Kee Hospital, operational since 2013, is also a tertiary hospital and has received various certifications, including from the Joint Commission International (JCI) [2]. Financial Performance - Revenue for Ming Kee Hospital was approximately RMB 2.336 billion in 2022, RMB 2.688 billion in 2023, and RMB 2.659 billion in 2024, with RMB 1.330 billion and RMB 1.312 billion for the six months ending June 30 in 2024 and 2025, respectively [5]. - Profit figures were RMB 89.55 million in 2022, approximately RMB 167.45 million in 2023, and approximately RMB 108.92 million in 2024, with RMB 63.40 million and RMB 48.70 million for the six months ending June 30 in 2024 and 2025, respectively [6]. - Gross profit margins were 16.4% in 2022, 18.9% in 2023, and 18.1% in 2024, with a margin of 15.9% for the six months ending June 30 in 2025 [7][9]. Industry Overview - The private hospital sector in China is predominantly for-profit, holding a market share of 66.5% in 2024. The revenue of private hospitals is projected to grow from RMB 437.9 billion in 2019 to RMB 944.7 billion in 2024, with a compound annual growth rate (CAGR) of 16.6% [10]. - The number of private hospitals is expected to increase from 22,424 in 2019 to 27,652 in 2024, with a CAGR of 4.3% [13]. - The demand for higher quality medical services is anticipated to rise due to increasing disposable income and changing patient preferences, positioning private hospitals as key players in meeting this demand [13].